HLB BioStep Co

HLB BioStep Co Diluted EPS

The Diluted Earnings per Share of HLB BioStep Co (278650.KQ) as of Nov 18, 2026 is -1,122.39 KRW. In the previous year, Diluted Earnings per Share was -101.72 KRW — a change of 1,003.40% (lower).

Diluted EPS

-1,122.39KRW

YoY

1,003.40%

Last updated:

Diluted Earnings per Share of HLB BioStep Co is 2025 -1,122.39 KRW. Diluted Earnings per Share of HLB BioStep Co was 2024 -101.72 KRW. It decreases by 1,003.40% lower compared to the previous year.

The HLB BioStep Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
64.06 KRW
Jan 1, 2019
63.71 KRW
Jan 1, 2020
122.21 KRW
Jan 1, 2021
156.39 KRW
Jan 1, 2022
-42.47 KRW
Jan 1, 2023
-2.04 KRW
Jan 1, 2024
-101.72 KRW
Jan 1, 2025
-1,122.39 KRW
The HLB BioStep Co Diluted EPS history
YEARDiluted EPSYoY
-1,122.39KRW+1,003.40%
-101.72KRW+4,879.42%
-2.04KRW-95.19%
-42.47KRW-127.15%
156.39KRW+27.97%
122.21KRW+91.83%
63.71KRW-0.55%
64.06KRW-19.08%
79.16KRW+46.30%
54.11KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

Diluted Earnings per Share of HLB BioStep Co is -1,122.39 KRW in 2025.

Diluted Earnings per Share of HLB BioStep Co changed from -101.72 KRW to -1,122.39 KRW, representing a 1,003.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — HLB BioStep Co

All Key Metrics — HLB BioStep Co